Targeted Cancer
Diagnostics
Rapid, Point-of-Care Cancer Detection

About Us

OUR STORY
TimeLine_SBI_V4_edited.png
OUR VISION

Summit Biomedical Imaging is dedicated to improving early cancer detection using fluorescent targeted diagnostic agents. Our first target is oral cancer detection.

Our point-of-care oral diagnostic technology is fast, non-invasive, and extremely accurate. We empower clinicians to improve patient outcomes via early intervention.

69%

Of oral cancers are detected when metastatic

83%

5-year survival rate for localized disease

38%

5-year survival rate for metastatic oral cancer that has moved beyond the local tissue

 
 

Technology

Our proprietary technology is a fluorescent small molecule, PARPi-FL, that detects overexpression of PARP, a DNA repair enzyme, which is common in many cancers. Thus, our technology specifically targets oral cancer, enabling earlier, more accurate detection.

Technology_SchematicOverview.001.png

Pipeline

Summit Biomedical Imaging is developing targeted diagnostics for multiple cancers.

Pipeline_V5_edited.png
 

Management

Riley_Picture.jpg
Andrew Riley, J.D., Ph.D.
CEO & GC

Andrew Riley is the Chief Executive Officer and General Counsel of Summit Biomedical Imaging. Dr. Riley has more than ten years of experience working with pharmaceutical clients at a major, full-service law firm as a registered patent attorney. Prior to working as a patent attorney, Dr. Riley was a Senior Research Chemist at a major petrochemical company. Dr. Riley earned a J.D. from Fordham University School of Law and a Ph.D. from the University of California at Los Angeles.

 

Christian Brand, Ph.D.
CSO & Co-Founder

Christian Brand is a founding member and the Chief Scientific Officer of Summit Biomedical Imaging. After earning his Ph.D. from Georg-August-Universität Göttingen, Dr. Brand worked as a Post-Doctoral Research Scholar and Research Associate specializing in molecular imaging at Memorial Sloan Kettering Cancer Center. At Memorial Sloan Kettering Cancer Center, Dr. Brand developed and translated next-generation targeted cancer diagnostics and was involved in the submission of several successful IND applications to the FDA.

Headshot_Brand_2018_B1.jpg

Advisors

RMU head shot[1].jpg
Robert M. Unnold, M.B.A.
Executive Director

Bob Unnold is an entrepreneur with over 35 years of experience in business development. Bob has founded several successful companies and held a variety of management positions in those companies.  Bob’s experience includes navigating the challenges faced by early-stage startups through acquisition or going public. Bob earned an M.B.A. from St. John’s University.